MX390977B - Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo - Google Patents

Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo

Info

Publication number
MX390977B
MX390977B MX2017001396A MX2017001396A MX390977B MX 390977 B MX390977 B MX 390977B MX 2017001396 A MX2017001396 A MX 2017001396A MX 2017001396 A MX2017001396 A MX 2017001396A MX 390977 B MX390977 B MX 390977B
Authority
MX
Mexico
Prior art keywords
udenafil
patients
compounds
methods
myocardial performance
Prior art date
Application number
MX2017001396A
Other languages
English (en)
Other versions
MX2017001396A (es
Inventor
David J Goldberg
James L Yeager
Stephen M Paridon
Original Assignee
Mezzion Pharma Co Ltd
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd, Childrens Hospital Philadelphia filed Critical Mezzion Pharma Co Ltd
Publication of MX2017001396A publication Critical patent/MX2017001396A/es
Publication of MX390977B publication Critical patent/MX390977B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere generalmente al campo del uso de udenafilo o una sal farmaceuticamente aceptable del mismo en pacientes que se han sometido a la operacion de Fontan.
MX2017001396A 2014-08-12 2015-06-30 Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo MX390977B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036506P 2014-08-12 2014-08-12
US201562186132P 2015-06-29 2015-06-29
PCT/US2015/038638 WO2016025100A2 (en) 2014-08-12 2015-06-30 Methods of improving myocardial performance in fontan patients using udenafil compositions

Publications (2)

Publication Number Publication Date
MX2017001396A MX2017001396A (es) 2017-12-04
MX390977B true MX390977B (es) 2025-03-21

Family

ID=55301323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001396A MX390977B (es) 2014-08-12 2015-06-30 Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo

Country Status (24)

Country Link
US (7) US10137128B2 (es)
EP (2) EP4342531A3 (es)
JP (5) JP2017524705A (es)
KR (4) KR20230116098A (es)
CN (2) CN107073001A (es)
AU (3) AU2015302271B2 (es)
BR (1) BR112017002675A2 (es)
CA (5) CA3128691C (es)
CL (1) CL2017000329A1 (es)
CO (1) CO2017000271A2 (es)
DO (1) DOP2017000014A (es)
EA (1) EA201692518A3 (es)
EC (1) ECSP17015154A (es)
IL (2) IL285193B2 (es)
MX (1) MX390977B (es)
MY (1) MY200278A (es)
NZ (1) NZ765800A (es)
PE (1) PE20170469A1 (es)
PH (1) PH12017500120A1 (es)
SG (2) SG10202100300RA (es)
TN (1) TN2017000029A1 (es)
TW (5) TWI860641B (es)
UA (1) UA120514C2 (es)
WO (1) WO2016025100A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL285193B2 (en) 2014-08-12 2023-11-01 Mezzion Pharma Co Ltd Methods to improve heart muscle function in Fontan surgery patients using iodenafil compounds
US20170112857A1 (en) * 2015-10-27 2017-04-27 New Haven Pharmaceuticals, Inc. Extended Release Aspirin
KR102249155B1 (ko) 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물
MX2022003593A (es) * 2019-09-24 2022-09-19 Mezzion Pharma Co Ltd Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil.
AU2022325803A1 (en) 2021-08-13 2024-03-28 Goldberg, David J. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions
US20240285630A1 (en) * 2021-12-20 2024-08-29 Mezzion Pharma Co., Ltd. Methods and compositions for improving exercise performance

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
JP2009509984A (ja) 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
WO2007113243A2 (en) 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
KR20100029762A (ko) 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 ｐｄｅ 억제제
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
EP2512479B1 (en) 2009-12-18 2016-03-30 Exodos Life Sciences Limited Partnership Compositions for treating peripheral vascular disease
EP2556820A4 (en) 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
JP6469015B2 (ja) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド エネルギー代謝を増大させるための組成物および方法
IL285193B2 (en) 2014-08-12 2023-11-01 Mezzion Pharma Co Ltd Methods to improve heart muscle function in Fontan surgery patients using iodenafil compounds

Also Published As

Publication number Publication date
JP2025032254A (ja) 2025-03-11
CA3128705C (en) 2025-10-07
CN118436655A (zh) 2024-08-06
JP2024020187A (ja) 2024-02-14
US12048701B2 (en) 2024-07-30
DOP2017000014A (es) 2017-06-30
IL285193B2 (en) 2023-11-01
EP3180008B1 (en) 2023-11-29
KR20240122604A (ko) 2024-08-12
TW201617080A (zh) 2016-05-16
AU2015302271B2 (en) 2019-02-28
US20160045510A1 (en) 2016-02-18
US10653698B2 (en) 2020-05-19
CN107073001A (zh) 2017-08-18
US10137128B2 (en) 2018-11-27
IL285193A (en) 2021-08-31
TN2017000029A1 (en) 2018-07-04
IL250547A0 (en) 2017-03-30
US20190030038A1 (en) 2019-01-31
CA3128680A1 (en) 2016-02-18
PE20170469A1 (es) 2017-04-21
PH12017500120A1 (en) 2017-05-29
CA3128691A1 (en) 2016-02-18
TWI730944B (zh) 2021-06-21
NZ765800A (en) 2024-03-22
MY200278A (en) 2023-12-18
ECSP17015154A (es) 2017-05-31
EP4342531A2 (en) 2024-03-27
IL285193B1 (en) 2023-07-01
JP2019077726A (ja) 2019-05-23
AU2019203706A1 (en) 2019-06-20
KR20170066334A (ko) 2017-06-14
AU2021202212A1 (en) 2021-05-06
US20220047601A1 (en) 2022-02-17
EA201692518A2 (ru) 2017-07-31
CO2017000271A2 (es) 2017-05-31
TWI860641B (zh) 2024-11-01
CA3128697A1 (en) 2016-02-18
TW202400176A (zh) 2024-01-01
US20230095034A1 (en) 2023-03-30
EP4342531A3 (en) 2024-06-26
CL2017000329A1 (es) 2017-11-03
TWI767153B (zh) 2022-06-11
MX2017001396A (es) 2017-12-04
AU2015302271A1 (en) 2017-01-12
CA3128691C (en) 2025-10-07
CA3128680C (en) 2025-10-07
CA3128697C (en) 2025-10-07
UA120514C2 (uk) 2019-12-26
EA201692518A3 (ru) 2017-11-30
EP3180008A2 (en) 2017-06-21
WO2016025100A2 (en) 2016-02-18
IL250547B (en) 2021-07-29
JP2021091721A (ja) 2021-06-17
TW202118491A (zh) 2021-05-16
JP2017524705A (ja) 2017-08-31
CA3128705A1 (en) 2016-02-18
SG11201700060WA (en) 2017-02-27
US20180169103A1 (en) 2018-06-21
CA2954183C (en) 2023-10-31
BR112017002675A2 (pt) 2017-12-12
EP3180008A4 (en) 2018-01-24
KR20210038708A (ko) 2021-04-07
US20250064817A1 (en) 2025-02-27
US20190030037A1 (en) 2019-01-31
TW202224685A (zh) 2022-07-01
CA2954183A1 (en) 2016-02-18
TW202002982A (zh) 2020-01-16
KR20230116098A (ko) 2023-08-03
SG10202100300RA (en) 2021-02-25
NZ765796A (en) 2024-02-23

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
UY37051A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
CO2017003279A2 (es) Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
EA201691582A1 (ru) Новые фармацевтические препараты
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX2016006199A (es) Inhibidores de replicacion del virus de influenza.
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
NI201800071A (es) Compuestos de isoindol
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
MX2017014998A (es) Uso de hidroxido de potasio en el tratamiento de la queratosis actinica.
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis